ClinicalTrials.gg
CompletedNCT02866539Updated Apr 11, 2018

Effect of Polyherbal Compound for Control of Blood Sugar in Impaired Glucose Tolerance and Diabetes

An interventional study of Polyherbal capsule coccinia, bougainvillea, catharanthus and Placebo in Diabetes Mellitus, sponsored by Composite Interceptive Med Science. Completed at 1 site in India. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-04-11.

Sponsored by Composite Interceptive Med Science · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

The aim of the study is to control blood sugar with Sugar Balance capsules which is the leaves of three herbs: ivy ground (Coccinia indica)-200mg, bougainvillia (Bougainvillea spectabilis)-30mg, Madagascar periwinkle (Catharanthus rosea)-20mg.

02

Conditions studied

  • Diabetes Mellitus

Browse trials for

03

In context

Diabetes Mellitus

8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.

This study's enrollment of 122 is above the median of 80 across 6,023 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Composite Interceptive Med Science is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and non-pregnant females aged ≥30 years having a diagnosis of pre-diabetes (impaired fasting glucose or impaired glucose tolerance) and a diabetes and a meeting one of the following criteria

    1. Fasting Plasma Glucose ≥100 mg/dL, fasting is defined as no caloric intake for at least 8 h, OR
    2. 2-h Post load Glucose ≥140 mg/dL during an Oral Glucose Tolerance Test (OGTT). The test should be performed as described by the World Health Organisation(WHO), using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. OR
    3. Glycosylated () ≥5.7%. The test should be performed in a laboratory using a method that is National Accreditation Board for Testing and Calibration Laboratories certified and standardized. OR
    4. In a patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a random plasma glucose ≥200 mg/dL in the last 12 months.

Exclusion criteria

Exclusion Criteria:

  • Any one of the following

    1. History of diabetes onset >12 months from date of randomization and/or on any oral hypoglycemic agents (other than metformin)
    2. Any history suggestive of micro vascular or macro vascular disease
    3. Women in childbearing age unable to practice any form of
    4. Impaired renal function; estimated (eGFR) \<60mls/min/1.73m2.
    5. Known history of any chronic illness taking regular pharmacological agents.
    6. Blood pressure fluctuations exceeding 10 mmHg on 2 subsequent clinic visits or known history of hypotension or bradycardia in last 6 months or taking 2 or more antihypertensive medications regularly in the last 6 weeks
    7. Current or former employees of organic India
    8. Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
    9. Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Active comparator
    Polyherbal capsule

    Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.

    Drug: Polyherbal capsule coccinia, bougainvillea, catharanthus

  • Placebo comparator
    Placebo

    Placebo will contain an inert substance

    Drug: Placebo

Interventions

  • DrugPolyherbal capsule coccinia, bougainvillea, catharanthus

    A unique combination of 3 herbs that lower blood sugars

    Also known as: Sugar Balance (SB)

  • DrugPlacebo

    Similar looking inactive powder

06

What researchers measure

Primary outcomes

  1. Number of diabetes subjects achieving glycemic control

    a 0.5% reduction in baseline A1c and/or fasting plasma glucose below 125 mg/dl or 2 hour postprandial glucose \<180 mg/dl

    Time frame: 6 months

  2. Number of pre-diabetes achieving euglycemic status

    measured as A1c \< 5.7% and/or fasting plasma glucose \<100mg/dl/

    Time frame: 6 months

07

Study locations

1 site
  • Narayana Hrudayalaya Limited, Mazumdar Shaw multispecialty Hospital
    Bangalore, Karnataka 560099, India
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02866539
Lead sponsor
Composite Interceptive Med Science
Responsible party
Sponsor
First posted
Aug 15, 2016
Start date
Dec 2016
Primary completion
Dec 15, 2017
Completion
Jan 15, 2018
Last update
Apr 11, 2018

Study contacts

Alben Sigamani, MD
principal investigator · Narayana Hrudayalaya Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion